Cure HHT is proud to partner with Atavistik Bio as it advances ATV-1601, an investigational oral therapy for people with moderate to severe HHT. With Atavistik now joining the Cure HHT Clinical Trial Network, we will serve as the patient advocacy partner for the Harmony-HHT Phase 1/2 study—helping provide education, build awareness, and engage the global HHT community as the trial progresses.

Cure HHT is thrilled to share that the first patient has been dosed in Diagonal Therapeutics’ Phase 1/2 DIAMOND clinical trial evaluating DIAG723 for hereditary hemorrhagic telangiectasia (HHT). DIAG723 is designed to restore signaling in the pathway disrupted by the genetic mutations that cause HHT, with the potential to address the underlying biology of the disease rather than only managing its symptoms. The DIAMOND trial will evaluate the treatment’s safety and tolerability, as well as its preliminary effects on nosebleeds, anemia, and other HHT-related measures. For a community that currently has no approved treatment specifically for HHT, the launch of this trial represents an exciting and deeply meaningful step forward.

Cure HHT is the official patient advocacy partner aligned with this effort and is helping build awareness and interest across the global HHT community. Diagonal Therapeutics is also a partner in the Cure HHT Clinical Trial Network, making this the first clinical trial announcement to emerge from the network.

“This announcement belongs not only to the researchers and partners advancing this work, but also to the people affected by HHT who make progress possible,” said Marianne Clancy, Chief Executive Officer of Cure HHT. “Participating in an early-stage clinical trial requires tremendous courage, hope, time, and personal commitment. We are profoundly grateful to every individual and family who chooses to contribute to the development of new treatments—not only for themselves, but for the entire global HHT community and for generations still to come.”

Interested in the Study?

The DIAMOND trial is currently enrolling at clinical sites in Australia and New Zealand, but additional locations are expected to open around the world. Help Diagonal Therapeutics understand where interest is strongest—and where future trial sites could have the greatest impact—by completing Cure HHT’s clinical trial interest form.